Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 11/20 | 0.52 |
| ▸ | HAT1 | O14929 | 2/20 | 0.39 |
| ▸ | EP300 | Q09472 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6616745 | 0.84 | CDK2 (0.49) | SLC6A4 | |
| SCHEMBL6613385 | 0.77 | SLC6A4 (0.51) | SLC6A4 | |
| SCHEMBL27842093 | 0.72 | SLC6A4 (0.64) | SLC6A4 | |
| SCHEMBL6651084 | 0.72 | SLC6A4 (0.43) | SLC6A4 | |
| SCHEMBL6214018 | 0.71 | SLC6A4 (0.46) | SLC6A4 | |
| SCHEMBL6801437 | 0.71 | SLC6A4 (0.58) | SLC6A4 | |
| SCHEMBL6615509 | 0.71 | SLC6A4 (0.58) | SLC6A4 | |
| SCHEMBL9128867 | 0.71 | HTR1D (0.55) | SLC6A4 | |
| SCHEMBL8873321 | 0.69 | SLC6A4 (0.89) | SLC6A4 | |
| SCHEMBL6801031 | 0.68 | SLC6A4 (0.70) | SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1373203-A1 | CYCLOPROPYLINDOLE DERIVATIVES AS SELECTIVE SEROTONIN REUPTAKE INHIBITORS | Bristol-Myers Squibb Company (US) | 2004-01-02 | — | — | EP | claimed |
| WO-2002079152-A1 | CYCLOPROPYLINDOLE DERIVATIVES AS SELECTIVE SEROTONIN REUPTAKE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-10 | — | — | WO | claimed |
| US-20030073849-A1 | Cyclopropylindole derivatives as selective serotonin reuptake inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073849-A1 | Cyclopropylindole derivatives as selective serotonin reuptake inhibitors | HTR5A, HTR1A, HTR2C | SLC6A4 10/4885HAT1 4645/4885EP300 3450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.